01:20 PM EDT, 04/28/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our target to $121 from $151, 21.5x our 2026 EPS estimate. We keep our 2025 EPS estimate at $4.99, which stands at the high end of the reaffirmed guidance of $4.90 to $5.00, and we lower our 2026 EPS view to $5.64 from $5.71. RVTY reported better-than-expected Q1 2025 results today with Q1 EPS of $1.01 vs. $0.98 (+3% Y/Y) beating the consensus view of $0.95 driven by better-than-expected top-line revenue growth and margin performance. Q1 sales of $665M (+2% Y/Y) came in slightly above the consensus estimate of $662M. Life Sciences sales rose by 1% Y/Y due to growth in Pharma and Biotech, counterbalancing declines in Academic and Government. Diagnostics sales rose 3% Y/Y driven by HSD ImmunoDX and LSD Reproductive Health. RVTY raised its 2025 revenue guidance to $2.83B-$2.87B from $2.80B-$2.85B, which we find encouraging, given that peers are reducing forecasts due to ongoing uncertainties. We expect RVTY to achieve 3.4% Y/Y top-line sales growth in 2025, supported by its resilient business model.